Literature DB >> 10974014

Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache.

E D Rosen1, B M Spiegelman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10974014      PMCID： PMC381292          DOI： 10.1172/JCI10909

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  31 in total

Review 1.  Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

Authors:  J M Olefsky
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Lactic acidosis in patients with diabetes treated with metformin.

Authors:  R I Misbin; L Green; B V Stadel; J L Gueriguian; A Gubbi; G A Fleming
Journal:  N Engl J Med       Date:  1998-01-22       Impact factor: 91.245

3.  The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

Authors:  A Dunaif; D Scott; D Finegood; B Quintana; R Whitcomb
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

4.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

Authors:  A C Li; K K Brown; M J Silvestre; T M Willson; W Palinski; C K Glass
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

5.  Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats.

Authors:  E Shinohara; S Kihara; N Ouchi; T Funahashi; T Nakamura; S Yamashita; K Kameda-Takemura; Y Matsuzawa
Journal:  Atherosclerosis       Date:  1998-02       Impact factor: 5.162

6.  Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.

Authors:  K Berkowitz; R Peters; S L Kjos; J Goico; A Marroquin; M E Dunn; A Xiang; S Azen; T A Buchanan
Journal:  Diabetes       Date:  1996-11       Impact factor: 9.461

7.  The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

Authors:  M Ricote; A C Li; T M Willson; C J Kelly; C K Glass
Journal:  Nature       Date:  1998-01-01       Impact factor: 49.962

8.  PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

Authors:  C Jiang; A T Ting; B Seed
Journal:  Nature       Date:  1998-01-01       Impact factor: 49.962

9.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

10.  Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

Authors:  H Y Zhang; S R Reddy; T A Kotchen
Journal:  Hypertension       Date:  1994-07       Impact factor: 10.190
View more
  12 in total

1.  Inhibitory effect of deep-sea water on differentiation of 3T3-L1 adipocytes.

Authors:  Hee Sun Hwang; Seon Hwa Kim; Yung Geun Yoo; Yong Shik Chu; Yun Hee Shon; Kyung Soo Nam; Jong Won Yun
Journal:  Mar Biotechnol (NY)       Date:  2008-07-25       Impact factor: 3.619

2.  Leptin down-regulates peroxisome proliferator-activated receptor gamma (PPAR-gamma) mRNA levels in primary human monocyte-derived macrophages.

Authors:  Agatha Cabrero; Marta Cubero; Gemma Llaverías; Marta Alegret; Rosa Sánchez; Juan Carlos Laguna; Manuel Vázquez-Carrera
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

Review 3.  Peroxisome proliferator-activated receptors.

Authors:  Ouliana Ziouzenkova; Stephane Perrey; Niko Marx; Daniel Bacqueville; Jorge Plutzky
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 4.  Endothelial fatty acid transport: role of vascular endothelial growth factor B.

Authors:  Carolina Hagberg; Annika Mehlem; Annelie Falkevall; Lars Muhl; Ulf Eriksson
Journal:  Physiology (Bethesda)       Date:  2013-03

Review 5.  Oxidative stress and transcriptional regulation in Alzheimer disease.

Authors:  Qingli Shi; Gary E Gibson
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Oct-Dec       Impact factor: 2.703

6.  Genetic analysis of four novel peroxisome proliferator activated receptor-gamma splice variants in monkey macrophages.

Authors:  Jiming Zhou; Katina M Wilson; Jheem D Medh
Journal:  Biochem Biophys Res Commun       Date:  2002-04-26       Impact factor: 3.575

Review 7.  Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management.

Authors:  Samuel Dagogo-Jack
Journal:  J Natl Med Assoc       Date:  2003-09       Impact factor: 1.798

8.  Adipocyte pyruvate dehydrogenase kinase 4 expression is associated with augmented PPARγ upregulation in early-life programming of later obesity.

Authors:  Mark J Holness; Gulrez Zariwala; Celia G Walker; Mary C Sugden
Journal:  FEBS Open Bio       Date:  2012-03-05       Impact factor: 2.693

9.  Inhibition of preadipocyte differentiation and adipogenesis by zinc-α2-glycoprotein treatment in 3T3-L1 cells.

Authors:  Hui-Juan Zhu; Hui-Hua Ding; Jie-Ying Deng; Hui Pan; Lin-Jie Wang; Nai-Shi Li; Xiang-Qing Wang; Yi-Fan Shi; Feng-Ying Gong
Journal:  J Diabetes Investig       Date:  2013-02-27       Impact factor: 4.232

10.  The Korean Mistletoe (Viscum album coloratum) Extract Has an Antiobesity Effect and Protects against Hepatic Steatosis in Mice with High-Fat Diet-Induced Obesity.

Authors:  Hoe-Yune Jung; Yu-Hee Kim; In-Bo Kim; Ju Seong Jeong; Jung-Han Lee; Myoung-Sool Do; Seung-Pil Jung; Kwang-Soo Kim; Kyong-Tai Kim; Jong-Bae Kim
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-11       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.